Key figures in biotech, pharma, and medical devices were contacted by STAT reporters regarding President-elect Trump’s choice of Martin “Marty” Makary as commissioner of the FDA. Makary is part of the “Make America Healthy Again” movement and has been critical of some Covid-19 measures. Jared Holz, a health care strategist at Mizuho Securities, believes that Makary’s appointment will promote technology and innovation in drug review and approval processes. While some individuals spoke on the condition of anonymity, overall, there is a positive outlook on Makary’s appointment and his potential impact on the industry’s regulatory landscape.
Source link
Biotech and pharma react with relief to Makary as FDA commissioner
